ArticleProstate cancer2022

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.

Rahul Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.